Replies to post #24669 on Cytodyn Inc (CYDY)

[finesand]

Ram Selvaraju didn't yet make an assessment on the expansion value

I like him keeping track of company development. His numbers are based on similar fundamentals as shown in our evaluation, but he uses a 'licensing out' business model resulting in lower profits - hence his $1.50 - $2 low PT. Note his 80% chance of success, 20% discount only.
The other late analyst National Securities (OPN)has a $3 PT.

Curious what Ram will post on the cancer expansion. Should be good.